In a groundbreaking study published in Medical Cannabis and Cannabinoids, researchers in Medellin, Colombia, found that daily sublingual CBD oil significantly reduced neuropsychiatric symptoms (NPS) like agitation, anxiety, and depression in patients with Alzheimer’s Disease (AD).
OG Article: here
View our Fair Use Policy: here
This long-term study observed 65 AD patients who had not responded well to conventional treatments. Over a period of up to 24 months, 95% of participants achieved a reduction in their NPS severity scores by more than 30% within the first three months, with these improvements sustained for the entire study period.
The research team noted this study as the first of its kind with such a large sample size and an extended follow-up period. The median effective daily dose was 111 mg, showing benefits regardless of patient demographics or prior severity of symptoms. While the results support the efficacy and safety of CBD oil for AD-related NPS, the authors emphasize the need for further confirmation through randomized controlled clinical trials.
Previous studies have also indicated the benefits of oral synthetic THC (dronabinol) and THC-dominant extracts for reducing Alzheimer’s-related agitation, adding to the body of research supporting cannabinoid use in neuropsychiatric care for AD patients.
ความคิดเห็น